1.   2005 Thirty-Seventh Postdoctoral fund (NO.2005037103)

2.    2014 Award from Associates for Breast andProstate Cancer Research

3.    2014 Award from Margie and Robert E.Petersonbreast cancer program

4.    中国医学科学院药物所引进人才科研基金（110万）

5.    国家自然科学基金 (81573454) （60万）

6.    北京市自然科学基金（7172142）（20万）

7.    “重大新药创制”国家科技重大专项项目，2013ZX09402203、现代中药创新集群与数字制药技术平台、2013/01-2016/12 （20万）

8.   中国医学科学院医学与健康科技创新工程（2050万）

9.    “协和学者”特聘教授研究基金 （110万）

10.  活性与功能国家重点实验室”研究基金（40万）

11.  “十三五”重大新药创制（139万）

12.  人工智能辅助药物发现与研究 （90万）

一、发表论文：

 1. Jinhua Wang*,Ying Qu*, Partha S. Ray et al. Thioredoxin-like 2 regulates human cancer cellgrowth and metastasis via redox homeostasis and NF-κB signaling. Journal of Clinical Investigation.2011;121(1):212-225. (The article waselected as highlighted article) (IF: 15.366)

2. Jinhua Wang,Wan Li, Ying Zhao et al. Members of FOX family could be drug targets ofcancers. Pharmacol Ther. 2018 Jan;181:183-196. (IF: 11)

3. Xiangjin Zheng, Wan Li, Liwen Ren, Jinyi Liu Jinhua Wang*. The Sphingosine Kinase-1/ Sphingosine-1-Phosphate Axis in Cancer: Potential Target for AnticancerTherapy. Pharmacology & Therapeutics.2019 Mar;195:85-99. (IF: 10.376).

4. P.S Ray, JinhuaWang, Ying Qu, et al. Role of FOXC1 in regulation of   basal-like/triple-negative breast cancer. Journal of Clinical Oncology. 2009; 27:562S (No 15S, Part I of II). (IF: 17.255)

5. Jensen TW, Ray T, Wang Jinhua, Li X et al. Diagnosis of Basal-Like Breast CancerUsing a FOXC1-Based Assay. J Natl CancerInst. 2015 Jun 3;107(8). (IF：13.584)

6. Min Feng, Yi Bao, Zhimei Li, Jinhua Wang, Dave S.B. Hoon et al. RASAL2 activates RAC1 to promotetriple-negative breast cancer progression. JClin Invest. 2014; 124(12):5291-5304. (IF:13.261)

7. Iida Y, Ciechanover A, Jinhua Wang, Dave Hoon et al. Epigenetic Regulation of KPC1Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. Clin Cancer Res. 2017 Aug 15; 23(16):4831-4842.(IF: 9.619)

8. Jinhua Wang*, Partha S. Ray*, Ying Qu* et al. FOXC1 isa potential prognostic biomarker with functional significance in basal-likebreast cancer. Cancer Research.2010; 70(10):1-7. (The pictures in thearticle were chosen as the cover of magazine) (IF: 8.576)

9. Jinhua Wang,I Kuiatse, AJ Casa, AV Lee, X Cui. JNK, essential for anticancertherapy-induced apoptosis promotes cancer breast progession. Cancer Research. 2009; 69(suppl.):(2).January 15,2009 (IF：8.576)

10. Jinhua Wang,Sharon Hunag, Ling Takeshima et al. Acquire resistance to braf-inhibitor by increasingEGFR expression. Journal ofInvestigative Dermatology. 2015; 135:532-541. (IF: 7.216)

11. Jinhua Wang,Ying Qu, Xiaojiang Cui et al. FOXC1 regulates the functions of human basal-likebreast cancer cells by activating NF-kB signaling. Oncogene, 2012 Nov 8;31(45):4798-802. (IF: 7.18)

12. Wan Li, Liwen Ren, Xiangjin Zheng, Jinyi Liu, Jinhua Wang*, Tengfei Ji*, Guanhua Du*.3-O-Acetyl-11-keto-β-boswellic acid ameliorated aberrant metabolic landscapeand inhibited autophagy in glioblastoma. ActaPharmaceutica Sinica B, 2020, 10(2): 301-12. (IF:7.097)

13. Jinhua Wang, Wei hua, Sharon Huang etal. RASSF8 Regulates Progression of Cutaneous Melanoma through Nuclear Factor-κb. Oncotarget,2015:6:30165-30177. (IF: 6.63)

14. Jinhua Wang, Hirose H, Du G et al. P-REX1amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2pathway. Cancer Lett. 2017 Oct28;407:66-75. (IF: 6.491)

15. Jinhua Wang,Kelly K. Chong, Yoshitaka Nakamura et al. B7-H3 Associated with TumorProgression and Epigenetic Regulatory Activity in Cutaneous Melanoma. Journal of Investigative Dermatology.2013; 133(8):2050-8. (IF: 6.19)

16. ShuetTheng Lee, min feng, Jinhua Wang et al. Protein Tyrosine Phosphatase UBASH3B isOverexpressed in Triple-Negative Breast Cancer and Promotes Invasion andMetastasis. Proc Natl Acad Sci U S A.2013, Jul 2; 110(27):11121-6. (IF: 9.598)

17. Jian‑Li Chen,Han Zhang, Xue‑Qin Huang, Hong‑Ye Wan, Jie Li, Xing‑Xing Fan, Kathy QianLuo, Jinhua Wang, Xiao‑Ming Zhu1*, Jianfang Wang2*. Antiangiogenesis‑Combined PhotothermalTherapy in the Second Near‑Infrared Window at Laser Powers Below the SkinTolerance Threshold. Nano-Micro Lett. (2019)11:93(IF: 9.043)

18. Marzese DM, Scolyer RA, Jinhua Wang, Kawas NP et al.. Epigenome-wide DNA MethylationLandscape of Melanoma Progression to Brain Metastasis Reveals Aberrations onHomeobox D Cluster Associated with Prognosis. Human Molecular Genetics, 2013; 23(1): 226-38. (IF: 7.541)

19. KatsuyaOhta, Hiromitsu Hoshino, Jinhua Wang et al. MicroRNA-93activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma bydirectly inhibiting PTEN and CDKN1A. Oncotarget.2015:6(5):3211-24. (IF: 6.63)

20. Jinyi Liu，Xiangjin Zheng，Xiaocong Pang, Cui Yang, Jinhua Wang*. GD3s，a novel drug target of cancer.  ActaPharmaceutica Sinica B. 2018 Sep;8(5):713-720.（IF: 5.808 ） 

21. Wan Li, Jinyi Liu, Weiqi Fu, Xiangjin Zheng, LiwenRen, Shiwei Liu, Jinhua Wang*, Tengfei Ji*, Guanhua Du*. 3-O-acetyl-11-keto-β-boswellicacid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/Mphase. Journal of Experimental &Clinical Cancer Research. 2018 Jul 3;37(1):132 (IF: 5.646 )     

22. Wan Li, Jie Yi, Xiangjin Zheng, Shiwei Liu, WeiqiFu, Liwen Ren, Li Li, Dave S. B. Hoon, JinhuaWang*, Guanhua Du. miR-29c plays a suppressive role in breast cancer bytargeting the TIMP3/STAT1/FOXO1 pathway. ClinicalEpigenetics. 2018May 16;10:64.. (IF: 5.496 )                                 

23. Jie Yu, Jinhua Wang* et al. Overexpression ofNSUN2 by DNA hypomethylation is associated with metastatic progression in humanbreast cancer. Oncotarget. 2017 Mar28; 8(13):20751-20765. (IF: 5.168)

24. Jinhua Wang et al. Research progress onthe Forkhead Box C1. Oncotarget, 2017Nov 20;9(15):12471-12478.. (IF: 5.168)

25. Yi J,Gao R, Chen Y, Yang Z, Han P, Zhang H, Dou Y, Liu W, Wang W, Du G, Xu Y, Wang J*. Overexpression of NSUN2 by DNAhypomethylation is associated with metastatic progression in human breastcancer. Oncotarget. 2017 Mar28;8(13):20751-20765. (IF: 5.168)

26. Wang Jinhua,Li Li, Liu Shiwei, Zhao Ying, Wang Lin, Du Guanhua. FOXC1 promotes melanoma byactivating MST1R/PI3K/AKT pathway. Oncotarget.2016 Dec 20; 7(51):84375-84387. (IF:5.168)

27. Qin Tang, Liwen Ren, Jinyi Liu, Wan Li, XiangjinZheng, Jinhua Wang*, Guanhua Du*.Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cellsvia ATF4‐ATF3-CHOP axis. Cell Prolif.2019 Oct 23:e12706. (IF: 5.039)

28. Jin-yiLiu, Wei-qi Fu, Xiang-jin Zheng, Wan Li, Li-wen Ren, Jin-hua Wang*, Cui Yang* and Guan-hua Du*. Avasimibe exertsanticancer effects on human glioblastoma cells via inducing cell apoptosis andcell cycle arrest. Acta PharmacologicaSinica, 2020. (IF: 5.064)

29. Jinhua Wang,Isere Kuiatse, Adrian V. Lee et al. Sustained JNK Activity Promotes Epithelial-MesenchymalTransition, Invasion, and Survival of Breast Cancer Cells by Regulating  ERK Activation. (Molecular Cancer Research, 2010; 8(2):266-277). (The article was elected as highlightedarticle) (IF: 4.937)

30.Jie Yi, Liwen Ren, Dandan Li, Jie Wu, Wan Li, Guanhua Du, Jinhua Wang*.Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functionalsignificance in breast cancers [J]. Biomedicine & Pharmacotherapy,2020, 124(109827). (IF: 4.545)

31. Jinhua Wang*,Ying Qu*, Bingya Liu, Armando Giuliano et al. Elesclomol, counteracted by Aktsurvival signaling, enhances the apoptotic effect of chemotherapy drugs inbreast cancer cells. (Breast CancerResearch and Treatment, 2010; 121(2):311-21. (IF: 4.467)

32. Jie Yi, LiwenRen, Jie Wu, Wan Li, Xiangjin Zheng, Guanhua Du*, Jinhua Wang*.ApolipoproteinC1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. Ann Transl Med. 2019 Aug;7(16):380.(IF: 3.689)

33. Liwen Ren, Xiangjin Zheng, Jinyi Liu, Wan Li,Weiqi Fu, Qin Tang, Jinhua Wang∗, Guanhua Dua∗∗Network pharmacology study of traditional Chinesemedicines for stroke treatment and effective constituents screening. J Ethnopharmacol. 2019 Oct 5;242:112044.(IF: 3.414)

34. Jinhua Wang, WeiboKa, DaGong Sun et al.Synergistic effect of cytokines EPO, IL-3 and SCF on the proliferation,differentiation and apoptosis of erythroid progenitor cells. Clinical Hemorheology and microcirculation.2007; 37(4):291-9. (IF: 3.398)

35. Jinhua Wang, WeiboKa, Zhiyu Tang et al.Rheological studies on precursor cells at different stage in mice. Clinical Hemorheology and microcirculation.2003, 29:63-69. (IF: 3.398)

36. Jinhua Wang*, Xu Y, Li L et al. FOXC1is associated with estrogen receptor alpha and affects sensitivity of tamoxifentreatment in breast cancer. Cancer Med.2017 Jan; 6(1):275-287. (IF: 3.362)

37. Liwen Ren, JieYi, Wan Li, Xiangjin Zheng, Jinyi Liu, Jinhua Wang*, Guanhua Du*.Apolipoproteins and cancer. Cancer Med. 2019 Nov;8(16):7032-7043. (IF:3.357)

38.Wan Li#, Xiangjin Zheng#, Liwen Ren, Weiqi Fu, Jinyi Liu,Jun Xv, Shiwei Liu, Jinhua Wang*, Guanhua Du*. Epigenetichypomethylation and upregulation of GD3s in triple negative breast cancer [J]. Annalsof Translational Medicine, 2019, 7(23): 723.(IF: 3.297)

39. Wen Sun,Jinhua Wang, Ciuping Chen et al. Cytosoliccalcium mediates RIP1/RIP3 complex-dependent necroptosis through JNK activationand mitochondrial ROS production in human colon cancer cells. Free Radic Biol Med. 2017 Jul;108:433-444. (IF: 5.606)

40. Junke Song,Wen Zhang, Jinhua Wang, Haiguang Yang, Qimeng Zhou, Haigang Wang, Li Li,Guanhua Du*. Inhibition of FOXO3a/BIM signaling pathway contributes to theprotective effect of  salvianolic acid Aagainst cerebral ischemia/reperfusion injury. Acta Pharmaceutica Sinica B.2019,9:505-515.(IF: 5.808)

41. Xiaocong Pang,Weiqi Fu, Jinhua Wang, De Kang,LvjieXu,Ying Zhao, Ai-Lin Liu* and Guan-Hua Du*.Identification of Estrogen Receptor alphaAntagonists from Natural Products via In Vitro and In Silico Approaches. Oxidative Medicine and Cellular Longevity. (IF: 4.936) 

42. Xiaocong Pang,Ying Zhao, Jinhua Wang, Wan Li, Qian Xiang, Zhuo Zhang, Shiliang Wu,Ailin Liu*, Guanhua Du*, and Yimin Cui*. Competing Endogenous RNA andCoexpression Network Analysis for Identification of Potential Biomarkers andTherapeutics in association with Metastasis Risk and Progression of ProstateCancer.Oxid Med Cell Longev. 2019 Aug 5;2019:8265958. (IF: 4.868)

43. MarzeseDM, Liu M, Huynh JL, Wang J, MortonDL, Barkhoudarian G, Kelly DF, Hoon DS. Brain metastasis is predetermined inearly stage of cutaneous melanoma by CD44v6 expression through epigeneticregulation of the spliceosome. PigmentCell Melanoma Res. 2015 Jan; 28(1):82-93 (IF: 4.619)

44. Sanjay P. Bagaria*, Partha S. Ray*, Jinhua Wang, Alice Chung et al. Prognosticvalue of basal phenotype in HER2-overexpressing breast cancer. (Annual of surgical oncology, 2012;19(3): 935-40. (IF: 4.308)

45. Partha SRay*, Sanjay P Bagaria*, Jinhua Wang,Jaime M Shamonki. Basal-like breast cancer defined by FOXC1 expression offerssuperior prognostic value: a retrospective immunohistochemical study. (Annual of surgical oncology, 201118:3839–3847 (IF: 4.308)

46. Jingwen Zhang,Jinhua Wang, Diego M. Marzese, Xiaowen Wang, Zixiao Yang, Chunjie Li,Haibo Zhang, Jinsen Zhang, Clark C. Chen, Daniel F. Kelly, Wei Hua*, Dave S. B.Hoon*, Ying Mao*. B7H3 regulates differentiation and serves as a potentialbiomarker and theranostic target for human glioblastoma. LabInvest. 2019 Jul;99(8):1117-1129. (IF: 3.684)

47. BinXiao, Jin-HuaWang,Cheng-YanZhou, Jun-MiaoChen, NaZhang, NaZhao, Xiao-YanHan, Yi-XuanNiu,Yu-BaoFeng∗, Guan-HuaDua∗. Ethno-medicinal study of Artemisia ordosica Krasch. (traditionalChinese/Mongolian medicine) extracts for the treatment of allergic rhinitis andnasosinusitis. J Ethnopharmacol. 2019.112262. Epub 2019 Oct 1. (IF: 3.414)

48. Dagong Sun, JinhuaWang, Weijuan Yao et al. Tumorigenesis of murine erythroleukeiacell linetransfected with exogenous p53 gene. ClinicalHemorheology and microcirculation. 2004, 30:117-126. (IF: 3.398)

49. Junke Song, Wen Zhang, Jinhua Wang, Haiguang, Guanhua Du*. Activation of Nrf2 signaling by salvianolic acid C attenuates NF‑κB mediated inflammatory response both invivo and in vitro. International Immunopharmacology. 2018,63:299-310. (IF:3.118) 

50. Yang S, Wang J, Duanhua Du, et al. The naturalproduct bergenin ameliorates lipopolysaccharide-induced acute lung injury byinhibiting NF-kappaB activition. J. Ethnopharmacol.2017 Mar 22; 200:147-155. (IF: 2.981)

51. De Kang, Xiaocong Pang,Wenwen Lian, Lvjie Xu,Jinhua Wang, Hao Jia, Baoyue Zhang, Ai-Lin Liu*and Guan-Hua Du*.RSC Adv., 2018, 8, 5286. (IF: 2.936)

52. Jinhua Wang, WeiboKa, DaGongSun et al.Biochemical and biophysical studies on the precursor cells of mouseerythrocytes at different stages. CellBiochemistry and Biophysics. 2006, 45:147-156. (The article was elected as highlighted article) (IF: 2.7)

53. Jin-Hua Wang*,Qing-Shan Liu*, Jian Cui,Zhi-Hong Yang et al. A novel acute anemia model for pharmacological research inmice by compelled acute exercise. Acta PharmacologicaSinica. (2009) 30:1643-1647. (IF: 2.521)

54. FangyunSun* ,Xiuping Chen*, Jinhua Wang, etal. Arjunic acid, a strong free radical scavenger from Terminaliaarjuna. Am J Chin Med. 2008; 36(1):197-207291-9(IF: 1.969)

55. Jinhua Wang,WeiboKa, Dagong Sun et al Biophysical and biorheology studies on the precursorcells at different stages. Science inChina (Series. C). 2002, 45: 421-428. (IF:1.2)

56. Yepeng Luan*, Jinyi Liu, Jianjun Gao, JinhuaWang*. The Design and Synthesis of NovelPhenothiazine Derivatives as Potential Cytotoxic Agents [J]. Letters in DrugDesign & Discovery, 2020, 17:57-67.(IF: 1.169)

57. LinWang, Jinhua Wang, Guanhua Du et al.Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells byactivating P53 via decreasing P53-MDM2 complex. J Asian Nat Prod Res. 2017 Jun; 19(6):630-643. (IF: 1.071)

58. Wei CJ, Jinhua Wang, Guanhua Du et al. Synthesisand antitumor activities of sinomenine derivatives on rings A and C. J Asian Nat Prod Res. 2017 Nov 1:1-15. (IF: 1.071)

59. Chen X, Sun F, Ma L, Jinhua Wang, Qin H, Guanhua Du. In vitro evaluation on theantioxidant capacity of triethylchebulate, an aglycone from TerminaliachebulaRetz fruit. Indian Pharmacol. 2011May; 43(3):320-3. 291-9 (IF: 0.667)

60. 任利文，郑湘锦，李婉，王金华，杜冠华. 中药雷公藤毒性的历史认识与评价。医药导报（刊印中）

61. 伍友春，张昆，康志龙，赵新，王金华，许焕丽. 白花蛇舌草醇提物和半枝莲醇提物联用抗胰腺癌作用及机制研究 [J]. 药物评价研究, 2020, 43(7): 1233-8.

62.刘金宜,任利文,李莎,唐琴,李婉,郑湘锦,王金华,杜冠华.肿瘤免疫和代谢药物靶点研究进展[J].药学学报,2019,54(10):1718-1727.

63.富炜琦,王金华,李婉,王霖,杜冠华.中药苦木毒的历史认识与现代研究[J].中药药理与临床,2019,35(02):154-156.

64.郑湘锦,任利文,李婉,王金华,杜冠华.青风藤安全性研究进展[J].医药导报,2019,38(11):1430-1433.

65.刘金宜,富炜琦,杜冠华,王金华,杨淬.ST8Sia1基因过表达载体构建与鉴定及对人黑色素瘤细胞增殖的影响[J].中国药理学通报,2019,35(05):733-739.78.

66.王金华,李莉,杜冠华.中药天仙子的历史认识与评价[J].中药药理与临床,2018,34(05):163-165.

67. 于子茹,李莉,王金华,王振中,萧伟,杜冠华。桂枝茯苓胶囊原料药及其组分对人源乳腺癌细胞株增殖的影响。中国中西医结合杂志。2018年２月第３８卷第２期。

68. 周启蒙，王金华，杜冠华。两种晶型尼莫地平片剂在恒河猴体内药代动力学研究.药学学报，2017，52(12)：1918-1923.

69. 刘师伟,王金华,杨静。Vaspin 和肥胖及 2 型糖尿病.中华内分泌代谢杂志2011(27).No.5.

70. 王金华，蒋玉辉，唐志宇，曾柱。生长发育过程中血细胞流变学特性的研究进展( 综述 ).中国生物医学工程学报2006(25).No.2.

71. 王金华，韩光亮，张天泰，杜冠华。基于FP法的EPOR 配体高通量筛选模型.中国药理学通报2006 Jan；22（1）：114~7.

72. 王金华，孙芳云，杜冠华。诃子的药理作用研究进展.中国民族医药杂志1006-6810(2006)06-0045-03

73. 王金华，杜冠华。促红细胞生成素的信号传导及其生物学作用的研究进展.医学分子生物学杂质2005，2（6）：440-443.

74. 王金华,喀蔚波,孙大公等.用激光衍射法测量网织红细胞膜剪切弹性膜量(E)及表面粘度(μm).中国生物医学工程学报 2005年24卷04期 468-471.

75. 王金华,喀蔚波,孙大公等.不同发育阶段红系造血细胞的流变特性的研究.中国生物医学工程学报 2004(23).No.1.

76. 王金华,喀蔚波,唐志宇等.小鼠网织红细胞微观流变学特性的研究.生物物理学报2004年第3期 173-177.

77. 王金华,岳黎,唐军民等.CFU及其分化细胞的生物物理特性.生物物理学报 2003（19）367-371.

78. 王金华,姚伟娟,喀蔚波.红细胞和内皮细胞的粘附研究进展.北京生物医学工程 2001（20）302-305.

79. 王金华,喀蔚波孙大公文宗曜.病理条件下白细胞与内皮细胞的粘附.中国血液流变学杂质2000；10(4).

80. 孙芳云,王金华,张斌,梁智,秦海林,杜冠华.大花红景天的抗氧化性溶血作用研究.中药药理与临床2006；22（3、4）.

81. 岳黎敏,唐军民,苏安英,唐岩,王金华,汪涛,文宗曜.新型CKLF1对家兔红系造血祖细胞增殖分化的影响解剖学报2004（35）04-382.

二、国际专利：

Patent 1:METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATICBASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES （Patent No. US 9074253 B2  授权日：2015.7.7）.

Patent 2:DIAGNOSIS OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCERTYPES  （Patent No. EP 2486149B1  授权日：2015.6.17）.

三、国内专利：

专利1：醉茄素A在制备预防或治疗胶质母细胞瘤药物中的应用。王金华等。申请号：201810266304.0

专利2：乳香酸及其衍生物的制备与其抗神经胶质瘤的用途。王金华等。申请号：201810581480.3

专利 3：阿伐麦布在制备预防或治疗胶质母细胞瘤药物中的应用。王金华等。申请号：201811248470.4

专利 4：载脂蛋白C 1在作为胃癌诊断及预后评价生物标记物中的应用。王金华等。申请号：201910163695.8

专利 5：青藤碱类化合物在制备预防或治疗神经胶质瘤药物中的应用。王金华等。申请号：201910671599.4

专利 6：三个唑类化合物在制备抗神经胶质瘤药物中的应用。王金华等。申请号：202010189295.7

专利 7：黄芩素在制备预防和/或治疗新冠病毒感染疾病的药物中的应用。杜冠华，吕扬….王金华等。申请号：202010133944.1

四、参编专著：

1.  丹参大全. ISBN:978-7-117-09935-6/R.9936. 2008, Page: 242-248

2.  人类疾病动物模型. ISBN: 978-7-81116-231-8.   2007, Page: 88-85

3. 《天然小分子药物-源自于植物的小分子药物》副主编 2018

4. 《中药材“毒”之古今研究概评》2018

5.  《Nature small molecule drugs from plants》 2018

6.  《中国医学科技发展报告》2019